Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?
What it means
- What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
- How the stock is trading: $CRL +3.64% in the latest session.
- Timing: It came out pre-market, so the next session was the first that could react.
Where the stock stands
$CRL last traded at $350.85, +3.64% on the session. That puts it 7.6% shy of its 52-week high of $379.63 and 140% clear of its low of $146.20 — in the upper part of the range. Over the year it has ranged 160% from low to high: a very wide band — this one has spent the year on a roller coaster, and big swings are business as usual. These are latest-session quotes, not live prices — the live tape is on the $CRL page.
How much coverage it is getting
Nothing else on $CRL in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories from the same name or desk are listed beside this one.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$CRL earnings tomorrow, Monthly options expiration in 17 days and FOMC decision in 36 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the hard numbers get the last word soon.
What to watch next
For the receipts, the $CRL page has the full chart, the filings and the valuation model these figures come from. Comparing how two or three outlets frame the same story is the fastest way to separate the facts from the angle. Wook AI, above, can pull live figures and run the numbers on request — how far $CRL is from its high, or how this week's coverage compares.
How this analysis was made
Yahoo Finance published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $CRL. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Yahoo Finance published this on August 26, 2026. $CRL has moved +18.89% ($295.10 to $350.85). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.